Immunome Inc. (IMNM)
IMNM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/0001193125-26-088172-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | IMNM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001472012 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $6.9M |
| Net income | -$212.4M |
| Operating income | -$224.1M |
| Net margin | -3060.0% |
| Operating margin | -3228.8% |
| Revenue growth | -23.2% |
| Cash | $653.5M |
| Total assets | $683.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 299.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $212.8M cash; operating cash flow -$57.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 118,072,943 (2026-11-04); 91,710,277 a year earlier; 42,729,847 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-17 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.3M, sold $27.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$85.8M | -$60.8M | $212.8M | No debt tags | $0 | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $0 | -$73.1M | -$61.7M | $217.7M | No debt tags | $0 | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$53.8M | -$58.6M | $582.7M | No debt tags | $4.0M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $0 | -$69.9M | -$48.0M | $653.5M | No debt tags | $6.9M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $0 | -$57.5M | -$40.5M | $272.6M | No debt tags | $9.7M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $4.0M | -$43.4M | -$49.4M | $143.9M | No debt tags | $12.6M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $2.9M | -$41.6M | -$53.1M | $257.6M | No debt tags | $10.9M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $2.7M | -$80.2M | -$42.1M | $143.4M | No debt tags | $9.0M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-11-09 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 465 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.3% |
| 1 month | +6.8% |
| 3 months | -29.0% |
| Year to date | -12.6% |
| 1 year | +13.7% |
| From 52-week high | -37.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc | $15.48 | -1.59% | $2.1B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| SDGR | Schrodinger Inc. | $27.36 | -7.35% | $2.1B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| SEPN | Septerna Inc. | $41.67 | -2.18% | $2.0B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $46.56 | -1.15% | $2.0B |
| VERA | Vera Therapeutics Inc. | $26.97 | -4.02% | $1.9B |
| HRMY | Harmony Biosciences Holdings Inc. | $32.96 | -2.37% | $1.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier